Repare Therapeutics : Initial TRESR data provide clinical pr

Initial TRESR data provide clinical proof of concept and validate Repare Therapeutics' SNIPRx platform for molecular selection of tumors for therapy with RP-3500


... | October 8, 2021

Related Keywords

Montreal , Quebec , Canada , Houston , Texas , United States , Cambridge , Cambridgeshire , United Kingdom , David Rosen , Timothy Yap , Maria Koehler , Kimberly Minarovich , Lloydm Segal , Steve Forte , Division Of Cancer Medicine , Company Nasdaq , Company Virtual Webcast Event , Md Anderson Cancer Center , Repare Therapeutics Inc , Exchange Commission , Virtual International Conference On Molecular , Institute For Applied Cancer Science , Department Of Investigational Cancer Therapeutics , Company Quarterly , Repare Therapeutic , Virtual Webcast Event Today , Repare Therapeutics , Treatment Enabled , International Conference , Molecular Targets , Chief Medical Officer , Chief Executive Officer , Initial Findings , Virtual Webcast Event , Principal Investigator , Medical Director , Applied Cancer Science , Associate Professor , Investigational Cancer Therapeutics , Cancer Medicine , Cancer Center , Private Securities Litigation Reform Act , Quarterly Report , Repare Therapeutics Inc Stock Exchange , News , Information , Press Release , Nitial , Presr , Data , Rovide , Linical , Roof , F , Concept , End , Validate , Prepare , Niprx , Platform , Or , Olecular , Election , Rumors , Therapy , Ith Rptx Us7602731025 ,